Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers

Experience with oral tofacitinib in severe alopecia areata with different clinical responses

(2021) Didem Dincer Rota et al.   Journal of Cosmetic Dermatology

An integrated scalp and blood biomarker approach suggeststhe systemic nature of alopecia areata

(2021) Jacob W. Glickman et al.   ALLERGY

A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results

(2021) Brett King et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Cross-sectional study of blood biomarkers of patients with moderate-to-severe alopecia areata reveals systemic immune and cardiovascular biomarker dysregulation

(2020) Jacob W. Glickman et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Cell surface IL‐1α trafficking is specifically inhibited by interferon‐γ, and associates with the membrane via IL‐1R2 and GPI anchors

(2020) Julie N.E. Chan et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

PF-06651600, a dual JAK3/TEC family kinase inhibitor

(2019) Hua Xu et al.   ACS Chemical Biology

The profile of cytokines (IL‐2, IFN‐γ, IL‐4, IL‐10, IL‐17A, and IL‐23) in active alopecia areata

(2019) Ram Kishan Gautam et al.   Journal of Cosmetic Dermatology

Oral JAK/SYK-inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in atopic dermatitis

(2019) Ana B. Pavel et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Janus kinase inhibitors: An innovative treatment for alopecia areata

(2019) Hyunsun Park et al.   JOURNAL OF DERMATOLOGY

Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial

(2019) Robert Bissonnette et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Combination tofacitinib and oral minoxidil treatment for severe alopecia areata

(2019) Carlos G. Wambier et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases

(2019) Kata P. Szilveszter et al.   Frontiers in Immunology

Experience with oral tofacitinib in two adolescents and seven adults with alopecia areata

(2019) Neslihan Akdogan et al.   Dermatologic Therapy

Targeting the Janus Kinase Family in Autoimmune Skin Diseases

(2019) Michael D. Howell et al.   Frontiers in Immunology

Early-onset pediatric atopic dermatitis is characterized by T H 2/T H 17/T H 22-centered inflammation and lipid alterations

(2018) Patrick M. Brunner et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

An Integrated model of Alopecia Areata biomarkers highlights both Th1/Th2 up-regulation

(2018) Teresa Song et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis

(2018) A. Jabbari et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Alopecia areata

(2018) Lauren C. Strazzulla et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Atopic dermatitis in African American patients is TH2/TH22-skewed with TH1/TH17 attenuation

(2018) Riana D. Sanyal et al.   ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY

Dupilumab progressively improves systemic and cutaneous abnormalities in atopic dermatitis patients

(2018) Emma Guttman-Yassky et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab

(2018) Patrick M. Brunner et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)

(2018) Andrew Fensome et al.   JOURNAL OF MEDICINAL CHEMISTRY

Role of janus kinase inhibitors in the treatment of alopecia areata

(2018) Korn Triyangkulsri et al.   Drug Design Development and Therapy

Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study

(2018) Nawaf Almutairi et al.   DERMATOLOGY

Alopecia areata: What’s new in epidemiology, pathogenesis, diagnosis, and therapeutic options?

(2017) Teruki Dainichi et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Oral tofacitinib monotherapy in Korean patients with refractory moderate-to-severe alopecia areata: A case series

(2017) Hyun-Sun Park et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients

(2017) Lucy Y. Liu et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers

(2016) Ali Jabbari et al.   EXPERIMENTAL DERMATOLOGY

Biomarkers of alopecia areata disease activity and response to corticosteroid treatment

(2016) Judilyn Fuentes-Duculan et al.   EXPERIMENTAL DERMATOLOGY

Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism

(2016) Emma Guttman-Yassky et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Use of a proximity extension assay proteomics chip to discover new biomarkers for human atherosclerosis

(2015) Lars Lind et al.   ATHEROSCLEROSIS

Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib

(2015) Ali Jabbari et al.   EBioMedicine

Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition

(2014) Luzhou Xing et al.   NATURE MEDICINE

GSVA: gene set variation analysis for microarray and RNA-Seq data

(2013) Sonja Hänzelmann et al.   BMC BIOINFORMATICS

Alopecia Areata

(2012) Amos Gilhar et al.   NEW ENGLAND JOURNAL OF MEDICINE